Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) Director Sushil Patel sold 2,155 shares of the firm's stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $37.00, for a total transaction of $79,735.00. Following the completion of the sale, the director now owns 15,700 shares in the company, valued at $580,900. The sale was disclosed in a document filed with the SEC, which is available at this link.
Revolution Medicines Price Performance
Shares of Revolution Medicines stock opened at $36.07 on Friday. Revolution Medicines, Inc. has a 1 year low of $15.44 and a 1 year high of $38.73. The company's fifty day moving average is $31.13 and its two-hundred day moving average is $27.32.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.29). The business had revenue of $0.74 million for the quarter, compared to the consensus estimate of $1.20 million. During the same quarter in the prior year, the firm earned ($0.63) earnings per share. The business's revenue was down 95.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Revolution Medicines, Inc. will post -3.17 earnings per share for the current year.
Analyst Ratings Changes
Massive breakthrough for options traders.
From WealthPress | Ad
A 34 year old man from central florida has uncovered a totally new way to trade options…
Already this year it’s allowed real people to capture top returns of 50%...
100%...
Even 200% overnight…
Without using technical patterns, momentum, A.I. or any of the other commonly used strategies…
Now, it’s important to mention that nothing is 100% perfect in terms of trading.
Click here to see this stunning development for yourself.
A number of equities research analysts have recently weighed in on RVMD shares. UBS Group started coverage on shares of Revolution Medicines in a report on Wednesday, December 20th. They issued a "buy" rating and a $40.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and issued a $46.00 price objective (up from $36.00) on shares of Revolution Medicines in a report on Monday, April 8th. Piper Sandler initiated coverage on shares of Revolution Medicines in a research note on Monday, March 11th. They set an "overweight" rating and a $43.00 price target on the stock. Raymond James upgraded shares of Revolution Medicines from an "outperform" rating to a "strong-buy" rating and lifted their price target for the stock from $36.00 to $48.00 in a research note on Wednesday. Finally, Wedbush lifted their price target on shares of Revolution Medicines from $41.00 to $42.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $41.20.
Get Our Latest Research Report on Revolution Medicines
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of RVMD. MetLife Investment Management LLC grew its position in Revolution Medicines by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 34,256 shares of the company's stock worth $874,000 after purchasing an additional 12,643 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Revolution Medicines by 165.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 478,776 shares of the company's stock worth $12,214,000 after purchasing an additional 298,436 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Revolution Medicines by 3.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 444,212 shares of the company's stock valued at $11,332,000 after acquiring an additional 13,134 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Revolution Medicines by 12.3% in the first quarter. Northern Trust Corp now owns 629,849 shares of the company's stock valued at $16,067,000 after acquiring an additional 68,794 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Revolution Medicines by 3.2% in the first quarter. State Street Corp now owns 2,843,477 shares of the company's stock valued at $72,537,000 after acquiring an additional 88,844 shares in the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.
Revolution Medicines Company Profile
(
Get Free Report)
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
